stada arzneimittel ag
(STDAF:OTC Pink - Current Information)

Financial Statements for stada arzneimittel ag (STDAF)

Currency in Millions of Euros	As of:	Dec 31 2009 Reclassified EUR	Dec 31 2010 Reclassified EUR	Dec 31 2011 Reclassified EUR	Dec 31 2012 EUR	4 Year Trend
Revenues		1,568.8	1,627.0	1,715.4	1,837.5
TOTAL REVENUES		1,568.8	1,627.0	1,715.4	1,837.5
Cost of Goods Sold		845.4	862.2	883.9	928.5
GROSS PROFIT		723.4	764.8	831.5	909.1
Selling General & Admin Expenses, Total		468.8	503.2	529.1	602.0
R&D Expenses		46.6	49.4	50.3	52.1
Other Operating Expenses		-1.9	-10.0	-23.2	-0.3
OTHER OPERATING EXPENSES, TOTAL		513.5	542.6	556.3	653.8
OPERATING INCOME		209.9	222.2	275.2	255.3
Interest Expense		-61.9	-54.3	-59.7	-70.6
Interest and Investment Income		4.9	3.5	8.9	5.3
Other Non-Operating Expenses, Total		2.5	10.5	1.8	0.7
Other Non-Operating Income (Expenses)		6.9	0.3	1.2	-0.8
Impairment of Goodwill		--	-4.0	-1.9	-3.1
Gain (Loss) on Sale of Investments		-0.3	-4.1	--	--
Gain (Loss) on Sale of Assets		0.9	-0.5	1.0	0.2
Other Unusual Items, Total		-14.4	-64.2	-155.7	-52.1
EBT, INCLUDING UNUSUAL ITEMS		141.5	109.0	69.5	135.6
Income Tax Expense		40.8	40.5	47.1	48.6
Minority Interest in Earnings		-0.3	-0.1	-0.3	-0.5
Earnings from Continuing Operations		100.7	68.6	22.4	87.0
NET INCOME		100.4	68.4	22.0	86.5
NET INCOME TO COMMON INCLUDING EXTRA ITEMS		100.4	68.4	22.0	86.5
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS		100.4	68.4	22.0	86.5

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.